192 related articles for article (PubMed ID: 38892809)
1. Novel Therapeutic Strategies in Alzheimer's Disease: Pitfalls and Challenges of Anti-Amyloid Therapies and Beyond.
Tondo G; De Marchi F; Bonardi F; Menegon F; Verrini G; Aprile D; Anselmi M; Mazzini L; Comi C
J Clin Med; 2024 May; 13(11):. PubMed ID: 38892809
[TBL] [Abstract][Full Text] [Related]
2. Navigating the Alzheimer's Treatment Landscape: Unraveling Amyloid-Beta Complexities and Pioneering Precision Medicine Approaches.
Patwekar M; Patwekar F; Khan S; Sharma R; Kumar D
Curr Top Med Chem; 2024 Apr; ():. PubMed ID: 38644708
[TBL] [Abstract][Full Text] [Related]
3. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
4. Status and future directions of clinical trials in Alzheimer's disease.
Plascencia-Villa G; Perry G
Int Rev Neurobiol; 2020; 154():3-50. PubMed ID: 32739008
[TBL] [Abstract][Full Text] [Related]
5. Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer's Disease: A Focus on Aducanumab and Lecanemab.
Shi M; Chu F; Zhu F; Zhu J
Front Aging Neurosci; 2022; 14():870517. PubMed ID: 35493943
[TBL] [Abstract][Full Text] [Related]
6. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
[TBL] [Abstract][Full Text] [Related]
7. Targeting Abnormal Tau Phosphorylation for Alzheimer's Therapeutics.
Singh A; Ansari VA; Mahmood T; Hasan SM; Wasim R; Maheshwari S; Akhtar J; Sheikh S; Vishwakarma VK
Horm Metab Res; 2024 Feb; ():. PubMed ID: 38350636
[TBL] [Abstract][Full Text] [Related]
8. Novel strategies for the fight of Alzheimer's disease targeting amyloid-β protein.
Xie Y; Wang Y; Jiang S; Xiang X; Wang J; Ning L
J Drug Target; 2022 Mar; 30(3):259-268. PubMed ID: 34435898
[TBL] [Abstract][Full Text] [Related]
9. A Recent Update on Pathophysiology and Therapeutic Interventions of Alzheimer's Disease.
Kashif M; Sivaprakasam P; Vijendra P; Waseem M; Pandurangan AK
Curr Pharm Des; 2023; 29(43):3428-3441. PubMed ID: 38038007
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances in the Modeling of Alzheimer's Disease.
Sasaguri H; Hashimoto S; Watamura N; Sato K; Takamura R; Nagata K; Tsubuki S; Ohshima T; Yoshiki A; Sato K; Kumita W; Sasaki E; Kitazume S; Nilsson P; Winblad B; Saito T; Iwata N; Saido TC
Front Neurosci; 2022; 16():807473. PubMed ID: 35431779
[TBL] [Abstract][Full Text] [Related]
11. Delivery of Intravenously Administered Antibodies Targeting Alzheimer's Disease-Relevant Tau Species into the Brain Based on Receptor-Mediated Transcytosis.
Tashima T
Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214143
[TBL] [Abstract][Full Text] [Related]
12. Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-β Cascade in Alzheimer's Disease.
Behl T; Kaur I; Fratila O; Brata R; Bungau S
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050199
[TBL] [Abstract][Full Text] [Related]
13. Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease.
de la Monte SM
Drugs; 2012 Jan; 72(1):49-66. PubMed ID: 22191795
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for Alzheimer's disease: targeting β-amyloid and beyond.
Song C; Shi J; Zhang P; Zhang Y; Xu J; Zhao L; Zhang R; Wang H; Chen H
Transl Neurodegener; 2022 Mar; 11(1):18. PubMed ID: 35300725
[TBL] [Abstract][Full Text] [Related]
15. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
16. Targeting Abeta and tau in Alzheimer's disease, an early interim report.
Golde TE; Petrucelli L; Lewis J
Exp Neurol; 2010 Jun; 223(2):252-66. PubMed ID: 19716367
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
[TBL] [Abstract][Full Text] [Related]
18. Tau Proteins and Tauopathies in Alzheimer's Disease.
Chong FP; Ng KY; Koh RY; Chye SM
Cell Mol Neurobiol; 2018 Jul; 38(5):965-980. PubMed ID: 29299792
[TBL] [Abstract][Full Text] [Related]
19. Alzheimer's Disease is Driven by Intraneuronally Retained Beta-Amyloid Produced in the AD-Specific, βAPP-Independent Pathway: Current Perspective and Experimental Models for Tomorrow.
Volloch V; Olsen B; Rits S
Ann Integr Mol Med; 2020; 2(1):90-114. PubMed ID: 32617536
[TBL] [Abstract][Full Text] [Related]
20. The impact of chelating compounds on Cu
Mazur T; Malik M; Bieńko DC
J Inorg Biochem; 2024 Aug; 257():112601. PubMed ID: 38744143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
